Semaglutide TFA Inhibitor

Name: Semaglutide TFA Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5753895
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753895

Semaglutide TFA is a agonist of glucagon-like peptide-1 (GLP-1) receptor,with a potential for type 2 diabetes treatment. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Semaglutide TFA, Inhibitor

Full Product Name

Semaglutide TFA

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

4210.63

Solubility

DMSO: 100mg/mL (23.75mM) Need ultrasonic
H2O: <0.1mg/mL (insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)

SMILES

OC(C(F)(F)F)=O.[Semaglutide]

Target & IC50

GLP-1 receptor

In Vitro

The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs[1]. 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairmentsimproved by Semaglutide. In addition, Semaglutide rescues the decrease of tyrosine hydroxylase (TH) levels, reduces lipid peroxidation, alleviates the inflammation response, inhibits the apoptosis pathway and increases autophagy- related protein expression, to protect dopaminergic neurons in the substantia nigra and striatum. Moreover, the long-acting GLP-1 analogue semaglutide is superior to liraglutide in most parameters[2]. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight[3].

Product Categories/Family for Semaglutide TFA, inhibitor

GPCR/G Protein; Glucagon Receptor

Product References and Citations for Semaglutide TFA, inhibitor

Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844.
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844.
Zhang L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model. Neuropeptides. 2018 Oct;71:70-80.
Zhang L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model. Neuropeptides. 2018 Oct;71:70-80.
Dhillon S, et al. Semaglutide: First Global Approval. Drugs. 2018 Feb;78(2):275-284.
Dhillon S, et al. Semaglutide: First Global Approval. Drugs. 2018 Feb;78(2):275-284.

Other Notes

Small volumes of Semaglutide TFA, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Semaglutide TFA purchase

MBS5753895 is an inhibitor targeting Semaglutide TFA.